960494-15-9

Basic information

• Product Name: D-Glucopyranose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-2,3,4,6-tetrakis-O-(triMethylsilyl)-
• Synonyms: D-Glucopyranose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-2,3,4,6-tetrakis-O-(triMethylsilyl)-;(3R,4S,5R,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-ol
• CAS NO: 960494-15-9
• Molecular Formula: C₃₃H₅₇ClO₇Si₄
• Molecular Weight: 713.59648
• Mol File: 960494-15-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: D-Glucopyranose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-2,3,4,6-tetrakis-O-(triMethylsilyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: D-Glucopyranose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-2,3,4,6-tetrakis-O-(triMethylsilyl)-(960494-15-9)
• EPA Substance Registry System: D-Glucopyranose, 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-2,3,4,6-tetrakis-O-(triMethylsilyl)-(960494-15-9)

Safety Data

• Hazardous Substances Data: 960494-15-9(Hazardous Substances Data)

Upstream product

• 90-80-2 D-Glucono-1,5-lactone 
• 103-73-1 Phenetole 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 999-97-3 1,1,1,3,3,3-hexamethyl-disilazane 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 

Downstream Products

• 1118566-45-2 (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol 
• 461432-25-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-26-8 dapagliflozin 
• 1079083-63-8 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-hydroxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-24-6 (3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents

The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Therefore, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of NO donor and SGLT2 inhibitor were design to achieve dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the preferred hybrid 2 exhibited moderate SGLT2 inhibitory effects and anti-platelet aggregation activities, and its anti-platelet effect mediated by NO was also confirmed in the presence of NO scavenger. Moreover, compound 2 revealed significantly hypoglycemic effects and excretion of urinary glucose during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 2, is expected as a potential candidate for the intervention of cardiovascular complications in T2DM.

PROCESS FOR PREPARATION OF DAPAGLIFLOZIN

The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.